Qualia Vision — Visual Health and Screen Time Protection
In the last couple of decades, the widespread use of computers, smartphones, and tablets has led to a tremendous increase in our exposure to screens. The type of light screens emit has also changed with the introduction of LEDs, which are more stressful for our visual system. Recent societal shifts have further exacerbated our already excessive screen exposure, including a greater engagement in digital leisure time activities, social media, remote learning, and working from home. All this has taken a heavy toll on our eyes and visual system.
If you routinely spend more than a couple of hours a day looking at a screen, chances are you’ve experienced a strain in your eyes after some time. You may have felt one or many of these manifestations: eye fatigue, itch, irritation or burning, dry eyes, teary or watery eyes, blurry or double vision, difficulty in focusing, sensitivity to light or glare.
Eye strain is a sign that your eyes are being pushed beyond their natural limits. Eye strain caused by screens is also known as digital eye strain or computer vision syndrome. It is often accompanied by other manifestations associated with long periods of computer use, such as throbbing sensations in the head, shoulder or neck, stiffness or other posture-associated issues, and brain and mood complaints such as fatigue, decreased focus, poor sleep quality, and irritability, for example.
Eye discomfort associated with screen time is a common complaint in people of all ages. Although there are many activities that can be challenging to the eyes, none is as stressful as staring at screens for extended periods of time. Because looking at screens is not really what our eyes are optimized for, these behaviors are straining and fatiguing the eyes and brain.
The Impact of Screens on The Eyes
Eye strain and fatigue are impacting a majority of adults and growing numbers of teens and children. Scientific studies have shown that over 60% (as high as above 90% in some studies) of people who use screens for work or school for moderate to long periods of time report eye strain [1–22].
The risk of eye strain is heavily influenced by the amount of time spent looking at screens—the longer the worse [8,16,23–30]. The stress placed by screens on our eyes accumulates throughout the day and starts to manifest as our eyes get tired. But screen stress also accumulates over weeks, months, and years of intense screen exposure [22,23,31–33]. In this case, it manifests as the gradual decline in visual health.
And although older age is a risk factor for eye strain [22,34], children and adolescents, with their intense use of computers, smartphones, video games, etc, are not impervious to eye strain. In fact, digital eye strain affects about 20-25% of children and teenagers [35–37].
The type of screen also influences eye strain, with smaller screens being more stressful. This is probably due to the fact that we usually use smaller screens closer to our eyes [38,39]—distance to the screen is another risk factor for eye strain, with shorter distances increasing the stress on the eyes [22,30].
But although there are many factors that influence how quickly you develop eye strain, and how intense eye stress may be, the fact is that if you spend enough time looking at screens, you’re likely to experience it. And most of us can’t really avoid staring at screens because we may have to use digital devices for work or for school (and increasingly for some social and leisure activities).
Why Did We Create Qualia Vision?
Being fully aware of the hurdles of screen time—we spend as much time looking at screens as anyone else—we wanted to create a product that would support and protect the health, resistance, and resilience of the visual system. We designed Qualia Vision to help our eyes cope with the challenges of the digital age. We aimed to create a product that would support eye health, visual performance, and resistance to visual fatigue and eye strain.
Qualia Vision is designed to support healthy vision with a main focus on screen time protection. Qualia Vision is designed especially for people of all ages who spend hours a day in front of devices with screens (e.g., smartphones, tablets, computers, TVs, video games, e-book readers, etc) and want protection from the eye stress that using these devices can cause.
To design Qualia Vision, we studied eye structure and function, the physiology of the visual system, and why and how screens affect visual performance and health to determine targets for intervention. We then chose a set of ingredients that could support visual health and performance, the physiological processes that are most affected by screen stress, and the mechanisms that are most relevant to the support of eye protection from screen time stress. We did so following the same formulation philosophy and dosing principles that have guided the design of all our products.
We ended up with nine ingredients that provide comprehensive vision support through a number of complementary and synergistic mechanisms:
- Lutemax® 2020 (a source of Lutein + Zeaxanthin + Meso-zeaxanthin)
- MirtoSelect® Bilberry (Vaccinium myrtillus) Fruit Extract
- AstaPure® Haematococcus pluvialis Microalgae Extract (3% Astaxanthin)
- Saffron Stigma Extract
- Goji (Lycium barbarum) Fruit Juice Extract
- Amla (Emblica officinalis) Fruit Extract
- Taurine
- Vitamin B12 (as Methylcobalamin)
- Ginger (Zingiber officinale) Root Extract
Let’s see how these ingredients support visual health and screen time protection.
Supporting Visual System Health
The visual system is the sensory system that enables vision. It includes the eyes—the sensory organ for vision—and the neuronal visual pathways of the brain, from the retinas to the cerebral cortex [40–42]. [If you want to learn more about the visual process, check out our article What Is Vision? An Overview of The Visual System and How We See.]
The eye is a complex organ with several different tissues, each with its own important function. All must be healthy for the eye itself to be healthy. But there are a few tissues that are particularly important for the visual process and particularly susceptible to the stress of screen time: the retina and the lens.
Figure 1 - Eye Structure. Source: Rhcastilhos and Jmarchn. Wikimedia Commons. Licence: CC BY-SA 3.0
The retina is the sensory tissue of the eye. It is a neural tissue and an extension of the brain. The retina has several types of neurons that contribute to the generation of the visual signal that is sent to the brain.
The light-sensitive sensory neurons that capture the energy of light (in the form of light particles or photons) and transduce it into neuronal impulses are called photoreceptors. Light energy is converted by photoreceptors into a change in membrane potential that, in turn, creates a neurochemical signal that is passed, within the retina, to bipolar neurons and then to ganglion cells. Ganglion cells are the output cells of the retina—their axons join to form the optic nerve which carries the visual information codified in the retina to the brain for further processing. The brain then translates these neuronal signals into mental images [40–42].
Figure 2 - Structure of the retina. Source (adapted): OpenStax, Anatomy and Physiology; 14.1 Sensory Perception. License: CC BY 4.0
Because the activity of the retina is central to the process of vision, supporting retinal sensory function was one of the main goals of Qualia Vision’s design. Healthy retinal function is supported by Lutemax® 2020 (Lutein + Zeaxanthin + Meso-zeaxanthin) [43,44], Mirtoselect® Bilberry Fruit Extract [45–52], Amla Fruit Extract [53], Goji Fruit Juice Extract [54–67], Ginger Root Extract [68], Vitamin B12 (Methylcobalamin) [149–151], Saffron Stigma Extract [69–71], AstaPure® Astaxanthin [72–74], and Taurine [75–84].
The retina, like the brain, is protected by a selective permeability barrier that restricts what can reach the retina through the blood: the blood-retina barrier, whose integrity is essential for healthy retinal function. Blood-retina barrier function and integrity is supported by Mirtoselect® Bilberry Fruit Extract [85] and Goji Fruit Juice Extract [61,62,86]. Goji also supports healthy retinal vasculature [58,87] and the proliferation of retinal progenitor cells (i.e., stem cells) [88].
A few Qualia Vision ingredients also support healthy optic nerve function, without which the brain wouldn’t receive input from the retina: Vitamin B12 (Methylcobalamin) [89–98], Goji Fruit Juice Extract [99] and Taurine [100].
The lens is a transparent convex disk whose function is to focus light on the retina. The lens is suspended within the eye, behind the pupil, by ligaments attached to the ciliary muscle, which forms a ring inside the eye.
The lens bends parallel light rays inwards, making them converge in a point called the focal point, and making that focal point fall at the depression (or pit) at the center of the retina called fovea, which is surrounded by a ring of pigmented tissue called macula. The lens changes its curvature to focus light of an object on the fovea to bring its image into sharp focus. The focal point must fall precisely on the retina for the object to be seen in focus. Changes in the shape of the lens are controlled by the ciliary muscle.
Figure 3 - Focal point. Source (adapted): BruceBlaus, Wikimedia Commons. Licence: CC BY 4.0
Healthy lens function is essential for visual quality. Lens health and function is supported by Amla Fruit Extract [101–103] and Goji Fruit Juice Extract [104,105]. Ginger Root Extract supports protection from advanced glycation end-products (AGEs) formation in the eye lens [106,107], which is important for the maintenance of lens health as we get older (AGEs are a biomarker of unhealthy aging in tissues).
The cornea—the transparent disk in the front of the eye that covers and protects the eye—is also supported by Qualia Vision ingredients, namely Mirtoselect® Bilberry Fruit Extract, which supports corneal cell function [108], AstaPure® Astaxanthin, which supports and protects corneal health and function [109–112], and Vitamin B12 (Methylcobalamin), which supports healthy function of eye ocular surfaces and corneal nerve [113,114].
Taurine is found in the cornea [115], where it acts as an antioxidant that protects the ocular surface [116]. Taurine is so important to corneal cell function that it can be actively taken up [117] and also be endogenously produced by corneal cells [118], but its levels decrease with age [119] and with light exposure [120]. Because taurine is actively taken up by corneal cells [117], supplementing taurine may help attenuate the impact of age-related and light-induced decreases in taurine levels.
Supporting The Effort of Near Vision
The process of adjusting the shape of the lens to keep objects in focus is known as accommodation and is controlled by the ciliary muscle. Accommodation determines the eye’s ability to quickly adjust focus as gaze is shifted between objects at different distances. To bring a close object into focus, the curvature of the lens is increased; for distant objects, lens curvature is decreased.
Screen use is a type of near vision, or near work, where we sustain focus at a near distance, often for hours on end. When the eyes are engaged in near work, three different responses operate together: (1) accommodation of the lens, (2) convergence of the eyes, and (3) constriction of the pupils. This is known as the near triad reflex or accommodation reflex.
Near vision and the sustained maintenance of near focus place a burden on the accommodation reflex. An intense muscular and nervous system effort is put into these responses to maintain our eyes focused on near objects. When this effort is prolonged, the eyes’ ability to adapt and recover is stressed, causing fatigue of ocular muscles, particularly of the ciliary muscle that works hard to maintain lens accommodation. Consequently, eye strain develops and visual performance declines. One clue that the ciliary muscle is tired is that, when shifting focus between objects near and far, instead of immediately coming into focus, there’s some blurriness.
Qualia Vision includes a group of ingredients that support the effort of near vision and lens accommodation. Ciliary muscle function is supported by Mirtoselect® Bilberry Fruit Extract [121] and Vitamin B12 (Methylcobalamin) [122]. AstaPure® Astaxanthin supports accommodation [123–125], as does Vitamin B12 (Methylcobalamin), which was shown to support accommodation when using devices with screens [122,126].
Because near work is associated with sustained visual attention, decreased blinking and poorer eye lubrication are often additional consequences of screen use. Blinking protects the ocular surface by secreting and spreading a film of tears over the surface of the eye, which allows us to perform visual tasks comfortably [127]. These tears also supply nourishment to the surface of the eye and help maintain corneal health [128].
Unfortunately, we blink much less often when looking at screens [129–135]. As a consequence, the corneal surface of the eye can dry out and become irritated or excessive tears may be produced to make up for decreased blinking. Supporting eye lubrication, which is one of the mechanisms of Mirtoselect® Bilberry Fruit Extract [136,137], can therefore be helpful in supporting resistance to eye strain and promoting comfort for the front of the eye.
Supporting Blue Light Protection
Screens are stressful in large part because of the light they emit and the amount of time we’re exposed to that light. LEDs in modern screens emit disproportionate amounts of blue light that’s stressful to the retina. Blue light causes a type of photochemical stress to the retina known as blue light hazard or retinal phototoxicity [138]. [You can learn about blue light phototoxicity in our article How Does Blue Light Affect Our Eyes? Understanding The Mechanisms of Blue Light Stress.]
Blue light stress involves an excessive generation of reactive oxygen species (ROS) in the retina. When ROS production is unbalanced, exceeding cells’ ability to neutralize them, cells fall into a state known as oxidative stress that can be stressful to retinal function [139]. Fortunately, the eye has a number of defenses that help mitigate the stress that can be caused by blue light.
Because the fovea and the macula form the central zone of the retina where the lens focuses light to generate sharp images, they are also the area of the retina most intensely exposed to light energy and thus most susceptible to blue light stress. To protect the fovea from light stress, macular pigments—lutein, zeaxanthin, and meso-zeaxanthin—absorb excess blue light, acting a bit like shade or blue-blockers for the retina, and thereby conferring protection to this area where light is focused and light energy is most intense [40–42,140].
One of the physiological functions of blue-light absorption by macular pigments is to act as optical filters for blue light and support visual performance by attenuating chromatic aberration, light scatter, veiling luminance, and blue haze induced by blue light [141–143]. But absorbing blue light has the added benefit of protecting from photostress. Macular carotenoids are also strong antioxidants, capable of scavenging ROS, countering oxidative stress, and thus providing antioxidant support to the retina [144–147].
Therefore, macular pigments have a key role in many functions important to eye health and visual performance [146–150]. Higher levels of macular pigments are linked to healthy macular function, visual performance during glare, and photostress recovery time (the time necessary to recover vision following exposure to a bright light) [141,142].
Lutein and zeaxanthin must be obtained from the diet. After we consume them, they accumulate in the macula; meso-zeaxanthin can be produced in the retina from lutein [146]. Therefore, adequate dietary levels of macular pigments are essential for a healthy visual response to blue light.
Figure 4 - Lutein and Zeaxanthin in visual health. Source (adapted): Loskutova E, et al. HRB Open Res 2019. Licence: CC BY 4.0
Supplementation with lutein, zeaxanthin, and meso-zeaxanthin supports macular pigment levels [151] and is a good way of supporting visual health and ensuring that our eyes’ ability to respond to blue light is at its best. This is why Qualia Vision includes Lutemax® 2020 in its formulation: because it supplies all three macular pigments—lutein, zeaxanthin, and meso-zeaxanthin. Macular carotenoid supplementation has been shown to support retinal and visual function and to support resistance to photostress, eye strain, and visual fatigue [43,44,152–165].
Qualia Vision includes other ingredients that have been shown to support responses to blue light and the antioxidant defenses needed to counter light stress. MirtoSelect® Bilberry Fruit Extract provides protective support against blue LED light-induced retinal photoreceptor cell stress through antioxidant defense pathways [50,166]. AstaPure® Astaxanthin supports the retina against light stress [167]. Saffron Stigma Extract promotes healthy retinal cell responses against light-induced stress by supporting antioxidant protection and by helping to maintain their morphology and function upon exposure to intense light [168–171]. Goji Fruit Juice Extract offers support from intense bright light for photoreceptor cells through the upregulation of antioxidant defenses [172,173]. Taurine supports photoreceptor cell responses to blue light-induced photooxidative stress [174,175].
Because of the high amounts of blue light stress produced by devices with screens, Qualia Vision was formulated to offer layers of blue light protection by combining Lutemax® 2020, MirtoSelect® Bilberry Fruit Extract, AstaPure® Astaxanthin, Saffron Stigma Extract, Goji Fruit Juice Extract, and Taurine. This was a major goal of our formulation.
Supporting Mitochondrial Function
The retina, like the brain, has massive energetic demands and its rate of oxidative metabolism is among the highest in the human body [176–178]. Therefore, retinal neurons, particularly photoreceptors, have large numbers of mitochondria to meet the high energetic requirements of sensory function.
Mitochondria are the cellular organelles responsible for the production of cellular energy in the form of ATP in a process known as oxidative phosphorylation. The mitochondrial electron transport chain (ETC) uses the energy of electron transfers to power the production of ATP. The ETC is also a major site of ROS production as a byproduct of energy metabolism [178,179].
Figure 5 - Mitochondrial electron transport chain. Source (adapted): Dw001 Wikimedia Commons. Licence: CC BY-SA 4.0
Mitochondria are one of the targets of blue light stress. Blue light can interact with neuronal mitochondria, impairing energy production and generating ROS [178], leading to a state of photooxidative stress that results in a snowball effect of mitochondrial dysfunction and ROS generation [178,179]. As a consequence, ATP production decreases and mitochondrial dysfunction progresses, eventually triggering degenerative processes within cells of the retina that can lead to tissue dysfunction [138,179–182].
Supporting mitochondrial function thus serves two purposes: it supports the generation of cell energy as ATP, helping mitochondria to meet the energetic demands of the retina and the brain; and it supports blue light protection in the retina by helping mitochondria to overcome the detrimental effects of blue light on their activity.
Qualia Vision includes a few ingredients that support mitochondrial function: Amla Fruit Extract supports mitochondrial function in the retina [53] and brain [183]; Goji Fruit Juice Extract supports retinal mitochondrial function [60,184]; Saffron Stigma Extract supports the activity of mitochondrial enzymes [185] and mitochondrial membrane potential [186]; AstaPure® Astaxanthin supports neural mitochondrial function [187–189] and mitochondrial responses to oxidative stress [190–192], Taurine supports neuronal mitochondrial function [193] and supports mitochondrial respiratory chain function [194,195].
Supporting Neuroprotection
Antioxidant defenses are key mechanisms of neuroprotection. The high metabolic activity of the retina has, as consequence, a high production of ROS as byproducts of energy metabolism. At balanced levels, ROS are important cellular signaling molecules. But when ROS levels fall off balance and accumulate, they cause oxidative stress and become potentially harmful [139].
Supporting antioxidant defenses—antioxidant enzymes, ROS scavengers, antioxidant defense signaling pathways— in the retina can be of great help in keeping ROS levels under control. But it’s not just the retina that is favored by the support of antioxidant defenses; other ocular tissues, particularly the lens, also benefit from antioxidant protection.
Several ingredients in Qualia Vision have been shown to support antioxidant defenses in the eye. Amla Fruit Extract supports antioxidant defenses of the retina and the lens [53]; MirtoSelect® Bilberry Fruit Extract supports retinal antioxidant defenses [50],
as does AstaPure® Astaxanthin [73,74], Goji Fruit Juice Extract [172,173], Taurine [77,100,196], and Saffron Stigma Extract [171,186,197].
Supporting membrane health is another important mechanism of neuroprotection. The structural and functional integrity of cellular membranes is a very important aspect of retinal function as virtually every aspect of neuronal function is linked to healthy membranes [40]. Retinal neuronal function is also highly dependent on membrane health for the actual initiation of the visual process [40,42].
Membrane health also plays a part in ROS production: unhealthy mitochondrial membranes can affect the efficiency of the ETC, which can lead to an unbalanced production of ROS [198]. And because of the high levels of oxidizable lipids that are found in neuronal membranes, retinal membranes are very susceptible to oxidation.
Supporting membrane health was an additional reason for the inclusion of Lutemax® 2020 and AstaPure® Astaxanthin in Qualia Vision. Lutein, zeaxanthin, and astaxanthin are potent membrane antioxidants. In neurons, lutein, zeaxanthin, and astaxanthin accumulate in cell membranes and axonal projections. They have structural characteristics that give them high solubility in cellular membranes and allow them to influence membrane properties such as fluidity and stability, as well as axon structure and neuronal communication [199–203]. So, in addition to their strong antioxidant activity, their support of neuroprotion can also be attributed to their membrane localization and how they interact with those membranes.
Cognition Support as An Outcome Of Vision Support
As neural tissue, the retina and the brain share characteristics that make them particularly vulnerable to oxidative stress, when compared to other tissues of the human body: both have very high metabolic activity that results in high ROS production and both rely heavily on the structural and functional integrity of cellular membranes.
Therefore, ingredients that support neuroprotective functions in the retina—both antioxidant defenses and membrane health—are likely to also end up supporting neuroprotective functions in the brain. And by doing so, these ingredients may also support healthy neuronal structure and function and neuronal communication [146,147,204], which are key aspects of cognitive function. [If you want to learn more about how visual health and cognitive health are connected, check out our article Can Your Eyesight Affect Your Brain? An Exploration of the Visual System And Cognitive Health.]
Because we were aware that support of cognitive function may be a secondary outcome of supporting vision, we wanted to work that into our formula. Therefore, we selected ingredients that have been shown to support not only vision, but also cognition or processes that contribute to cognitive function and health.
Several studies have shown that lutein and zeaxanthin supplementation, included in Qualia Vision as Lutemax® 2020, support cognitive function. Lutein and zeaxanthin supplementation was shown to support complex attention and cognitive flexibility in older adults [160]. In healthy young adults, lutein and zeaxanthin supplementation supported spatial memory, reasoning ability, and complex attention [157]. Lutein supplementation in adults also supported verbal fluency scores [205].
Figure 6 - Lutein and Zeaxanthin in cognitive health. Source (adapted): Loskutova E, et al. HRB Open Res 2019. Licence: CC BY 4.0
AstaPure® Astaxanthin supports learning and memory [4–8] and brain processes known to support cognitive performance, including sleep [9,10], hippocampal neurogenesis [6], neural stem cell function [18,19], brain-derived neurotrophic factor (BDNF) levels [11–16], neural mitochondrial function [21,26,27], and neuroprotective functions [17,20–26].
MirtoSelect® Bilberry Fruit Extract supports brain health and neuroprotective functions, including protection of cognitive health [206–209].
Goji Fruit Juice Extract supports neuroprotective functions [210–216], cognitive function [217], synaptic plasticity [216,218,219], neurogenesis [215,216,219], and cerebral blood flow [214].
Amla Fruit Extract supports cholinergic neurotransmission, brain mitochondrial function, neuroprotective functions, and cognitive health [183,220–226].
Taurine supports short-term memory [227], synaptic long-term potentiation [228], GABAergic neurotransmission [227,229–231], hippocampal neurotransmission [232], BDNF [227], cerebral blood flow [193], and neuronal mitochondrial function [193].
Saffron Stigma Extract supports cognitive health and performance (e.g., focus and attention [233]) by supporting neurotransmitter signaling [185,234], neuroprotective functions [185,235–239], long-term potentiation [240], sleep [240–242], and healthy brain aging [243–245].
Ginger Root Extract supports neuroprotective functions [246–249] and cognitive function [250,251].
Methylcobalamin, a coenzyme form of vitamin B12, is essential for the maintenance of healthy neuronal and axonal structure and function. Because vitamin B12 deficiency has been associated with poor neuronal and cognitive health [252], it’s important to support healthy brain levels of this vitamin.
Science-Backed Ingredients for Visual Health
Qualia Vision was designed to support eye health, screen time protection, visual performance, and resistance to visual fatigue and eye strain. Every ingredient in Qualia Vision is backed by scientific evidence showing support for relevant elements or mechanisms of visual health and performance and/or screen time protection.*
Lutemax® 2020—a source of Lutein + Zeaxanthin + Meso-zeaxanthin—is a clinically studied macular carotenoid product that supplies the three antioxidant macular pigments used by the macula to filter blue light and protect the retina. Lutemax® 2020 supports visual function [44,153–156,158,161–164], resistance to eye strain [162], resistance to visual fatigue [162,165], and photostress recovery [161].
Bilberry is a superfruit eye tonic from European herbal traditions rich in antioxidant polyphenols that support vision. MirtoSelect® is the most extensively studied bilberry extract on the market. MirtoSelect® Bilberry (Vaccinium myrtillus) Fruit Extract supports visual function [253–255], relief of eye fatigue [121,256], and ocular blood flow [257].
AstaPure® Haematococcus pluvialis Microalgae Extract (3% Astaxanthin) is a natural source of the xanthophyll carotenoid astaxanthin. Similar to the macular carotenoids, astaxanthin protects the eye from light and other stressors. Astaxanthin is an antioxidant that supports visual acuity [124,258], resistance to eye strain/fatigue [123], visual reaction time [259], blood flow to the eyes [260,261], and defenses against blue light [167].
Saffron is known for being the world’s most expensive spice, but it is also loaded with healthy bioactive compounds. Saffron extracts have been clinically studied for vision, mostly for age-related vision issues. Saffron Stigma Extract contains a variety of eye-healthy carotenoids and supports macular health [70,71,262] and retinal responses to intense light [168–171], important for screen stress resistance. Saffron also supports visual acuity [70,262].
Goji berry is a Traditional Chinese Medicine eye tonic used to nourish the eyes and promote healthy vision. Goji is rich in bioactive antioxidant compounds, including zeaxanthin—it’s considered one of the richest food sources of this macular pigment. Goji is also rich in polysaccharides, believed to be responsible for many of Goji’s health benefits, including the support of vision and eye health. Goji (Lycium barbarum) Fruit Juice Extract supports visual function [54,263,264] and healthy retinal and eye response to light [172,173].
Amla fruit is the eye Rasayana (i.e., rejuvenator) from Ayurvedic medicine. Amla supports lens health [101–103] and is believed to preserve eyesight, promote eye health, and relieve complaints related to eye strain and fatigue [265–267]. Amla (Emblica officinalis) Fruit Extract also supports DNA repair [268] and supports telomerase activity and telomere length [269], which are important properties for cell longevity.
Taurine is the most abundant amino acid in the retina (as well as other parts of the eye like the lens and cornea). The majority of the taurine pool of the retina is in photoreceptors, where taurine acts as an antioxidant and is essential for their light-capturing function [75]. Taurine supports resistance to visual fatigue [270]. Taurine also supports healthy cerebral blood flow [193].
Methylcobalamin is a coenzyme form of vitamin B12, a neuro-vitamin that is essential for healthy nerves. The eye has many important nerves whose function may be supported by methylcobalamin, particularly the optic nerve, which carries visual information to the brain [89–98]. Methylcobalamin supports visual function when using devices with screens [122,126].
Ginger, one of the most widely used spices in the world, contains many bioactive compounds that support visual health. Ginger (Zingiber officinale) Root Extract is a bioenhancer (it enhances the bioavailability of carotenoids) with antioxidant benefits that supports the healthy function of the retina and lens [68,106,107].
We believe that the combination of these ingredients creates synergies that allow Qualia Vision to offer comprehensive support of visual health and screen time protection.*
Qualia Vision—Meeting The Demands of Screen Time
Qualia Vision combines 9 carefully selected ingredients—vision antioxidants, blue-light protective ingredients, vision super fruits, Ayurvedic and Traditional Chinese Medicine eye rejuvenators, vision spices, and nootropics—to support healthy visual function and screen time stress resistance.*
Designed To
- Reduce eye fatigue and strain*
- Provide relief for tired, sore, or irritated eyes*
- Protect the front and back of the eyes from stress caused by blue light*
- Support visual performance in multiple areas (acuity, contrast, dim light vision, adjusting focus, near work endurance)*
- Enhance visual processing*
- Promote faster recovery from photostress*
- Promote healthy vision*
Key Features
- Supports retinal health and function *
- Supports macular pigment levels*
- Supports photoreceptor cell function*
- Supports retinal progenitor cells i.e., stem cells of the retina*
- Supports lens health and function *
- Supports the eye muscles involved in accommodation *
- Supports optic nerve health and function *
- Supports healthy mitochondrial function for cellular energy*
- Protects eye tissues from oxidative stress *
- Supports antioxidant defenses and neuroprotective functions *
- Supports cognitive function *
*These statements have not been evaluated by the Food and Drug Administration. The products and information on this website are not intended to diagnose, treat, cure or prevent any disease. The information on this site is for educational purposes only and should not be considered medical advice. Please speak with an appropriate healthcare professional when evaluating any wellness related therapy. Please read the full medical disclaimer before taking any of the products offered on this site.
References
[1] W.D. Thomson, Ophthalmic Physiol. Opt. 18 (1998) 111–119.
[2] A.H. Subratty, F. Korumtollee, Indian J. Occup. Environ. Med. 9 (2005) 71.
[3] R. Ustinaviciene, V. Januskevicius, Med. Sci. Monit. 12 (2006) CR296–301.
[4] J.R. Hayes, J.E. Sheedy, J.A. Stelmack, C.A. Heaney, Optom. Vis. Sci. 84 (2007) 738–744.
[5] B.M. Aakre, M.J. Doughty, Cont. Lens Anterior Eye 30 (2007) 174–182.
[6] D.J. Bhanderi, S. Choudhary, V.G. Doshi, Indian J. Ophthalmol. 56 (2008) 51–55.
[7] Z.A. Rahman, S. Sanip, Int J Bus Humanit Technol 1 (2011) 84–91.
[8] M.M. Moschos, I.P. Chatziralli, G. Siasou, L. Papazisis, Klin. Monbl. Augenheilkd. 229 (2012) 379–381.
[9] A. Toomingas, M. Hagberg, M. Heiden, H. Richter, K.E. Westergren, E. Wigaeus Tornqvist, Work 41 (2012) 3560–3562.
[10] J.K. Portello, M. Rosenfield, Y. Bababekova, J.M. Estrada, A. Leon, Ophthalmic Physiol. Opt. 32 (2012) 375–382.
[11] R. Akinbinu, Journal of Physiology and Pathophysiology 4 (2013) 58–63.
[12] M. Logaraj, V. Madhupriya, S. Hegde, Ann. Med. Health Sci. Res. 4 (2014) 179–185.
[13] P. Ranasinghe, W.S. Wathurapatha, Y.S. Perera, D.A. Lamabadusuriya, S. Kulatunga, N. Jayawardana, P. Katulanda, BMC Res. Notes 9 (2016) 150.
[14] A. Tauste, E. Ronda, M.-J. Molina, M. Seguí, Ophthalmic Physiol. Opt. 36 (2016) 112–119.
[15] A. Patil, Bhavya, S. Chaudhury, S. Srivastava, Ind. Psychiatry J. 28 (2019) 68–74.
[16] F. Larese Filon, A. Drusian, F. Ronchese, C. Negro, Int. J. Environ. Res. Public Health 16 (2019).
[17] H. Hashemi, M. Saatchi, A. Yekta, B. Ali, H. Ostadimoghaddam, P. Nabovati, M. Aghamirsalim, M. Khabazkhoob, J. Ophthalmic Vis. Res. 14 (2019) 474–482.
[18] H.-R. Moldovan, S.-T. Voidazan, G. Moldovan, M.-A. Vlasiu, G. Moldovan, R. Panaitescu, Arch. Environ. Occup. Health 75 (2020) 235–241.
[19] N. Cantó-Sancho, M. Sánchez-Brau, B. Ivorra-Soler, M. Seguí-Crespo, Int. J. Clin. Pract. (2020) e13681.
[20] S.B. Boadi-Kusi, P.O.-W. Adueming, F.A. Hammond, E.O. Antiri, Int. J. Occup. Saf. Ergon. (2021) 1–8.
[21] D. Fernandez-Villacorta, A.N. Soriano-Moreno, T. Galvez-Olortegui, N. Agui-Santivañez, D.R. Soriano-Moreno, V.A. Benites-Zapata, Arch. Soc. Esp. Oftalmol. (2021).
[22] H.A.M. Zayed, S.M. Saied, E.A. Younis, S.A. Atlam, Environ. Sci. Pollut. Res. Int. (2021).
[23] Shimai S., Iwasaki S., Takahashi M., Narita S., Suzuki H., Sangyo Igaku 28 (1986) 87–95.
[24] A.M. Rossignol, E.P. Morse, V.M. Summers, L.D. Pagnotto, J. Occup. Med. 29 (1987) 112–118.
[25] U.O. Bergqvist, B.G. Knave, Scand. J. Work Environ. Health 20 (1994) 27–33.
[26] T. Stüdeli, M. Menozzi, Int. J. Occup. Saf. Ergon. 9 (2003) 441–451.
[27] A. Toomingas, M. Hagberg, M. Heiden, H. Richter, K.E. Westergren, E.W. Tornqvist, Work 47 (2014) 291–301.
[28] E. Porcar, A.M. Pons, A. Lorente, Int. J. Ophthalmol. 9 (2016) 881–885.
[29] J.H. Choi, Y. Li, S.H. Kim, R. Jin, Y.H. Kim, W. Choi, I.C. You, K.C. Yoon, PLoS One 13 (2018) e0206541.
[30] P. Ganne, S. Najeeb, G. Chaitanya, A. Sharma, N.C. Krishnappa, Ophthalmic Epidemiol. (2020) 1–8.
[31] R. Iribarren, A. Fornaciari, G.K. Hung, Int. Ophthalmol. 24 (2001) 205–212.
[32] M. del Rosario Sánchez-Valerio, K. Mohamed-Noriega, I. Zamora-Ginez, B.G.B. Duarte, V. Vallejo-Ruiz, OPTH 14 (2020) 4311–4317.
[33] Y. Gammoh, Cureus 13 (2021) e13575.
[34] M. Sánchez-Brau, B. Domenech-Amigot, F. Brocal-Fernández, J.A. Quesada-Rico, M. Seguí-Crespo, Int. J. Environ. Res. Public Health 17 (2020).
[35] M.A.P. Vilela, L.C. Pellanda, A.G. Fassa, V.D. Castagno, J. Pediatr. 91 (2015) 320–325.
[36] M.A. Vilela, V.D. Castagno, R.D. Meucci, A.G. Fassa, Clin. Ophthalmol. 9 (2015) 1595–1603.
[37] P. Ichhpujani, R.B. Singh, W. Foulsham, S. Thakur, A.S. Lamba, BMC Ophthalmol. 19 (2019) 76.
[38] C. Tosha, E. Borsting, W.H. Ridder 3rd, C. Chase, Ophthalmic Physiol. Opt. 29 (2009) 625–633.
[39] Y. Bababekova, M. Rosenfield, J.E. Hue, R.R. Huang, Optom. Vis. Sci. 88 (2011) 795–797.
[40] M. Bear, B. Connors, M.A. Paradiso, Neuroscience: Exploring the Brain, Enhanced Edition, Jones & Bartlett Learning, 2020.
[41] Kandel, Principles of Neuroscience, 5th edition, McGraw-Hill, 2013.
[42] D.U. Silverthorn, Human Physiology: An Integrated Approach 8th Edition, Pearson, 2018.
[43] Age-Related Eye Disease Study 2 (AREDS2) Research Group, E.Y. Chew, T.E. Clemons, J.P. Sangiovanni, R.P. Danis, F.L. Ferris 3rd, M.J. Elman, A.N. Antoszyk, A.J. Ruby, D. Orth, S.B. Bressler, G.E. Fish, G.B. Hubbard, M.L. Klein, S.R. Chandra, B.A. Blodi, A. Domalpally, T. Friberg, W.T. Wong, P.J. Rosenfeld, E. Agrón, C.A. Toth, P.S. Bernstein, R.D. Sperduto, JAMA Ophthalmol. 132 (2014) 142–149.
[44] R. Liu, T. Wang, B. Zhang, L. Qin, C. Wu, Q. Li, L. Ma, Invest. Ophthalmol. Vis. Sci. 56 (2014) 252–258.
[45] F. Mazzolani, S. Togni, F. Franceschi, R. Eggenhoffner, L. Giacomelli, Minerva Oftalmol. 59 (2017) 38–41.
[46] O. Nakamura, S. Moritoh, K. Sato, S. Maekawa, N. Murayama, N. Himori, K. Omodaka, T. Sogon, T. Nakazawa, Clin. Ophthalmol. 11 (2017) 1825–1834.
[47] N. Matsunaga, S. Imai, Y. Inokuchi, M. Shimazawa, S. Yokota, Y. Araki, H. Hara, Mol. Nutr. Food Res. 53 (2009) 869–877.
[48] S. Miyake, N. Takahashi, M. Sasaki, S. Kobayashi, K. Tsubota, Y. Ozawa, Lab. Invest. 92 (2012) 102–109.
[49] H. Osada, T. Okamoto, H. Kawashima, E. Toda, S. Miyake, N. Nagai, S. Kobayashi, K. Tsubota, Y. Ozawa, PLoS One 12 (2017) e0178627.
[50] K. Ogawa, Y. Kuse, K. Tsuruma, S. Kobayashi, M. Shimazawa, H. Hara, BMC Complement. Altern. Med. 14 (2014) 120.
[51] Y. Wang, L. Zhao, F. Lu, X. Yang, Q. Deng, B. Ji, F. Huang, Molecules 20 (2015) 22395–22410.
[52] O.T. Mykkänen, G. Kalesnykas, M. Adriaens, C.T. Evelo, R. Törrönen, K. Kaarniranta, Mol. Vis. 18 (2012) 2338–2351.
[53] S. Nashine, R. Kanodia, A.B. Nesburn, G. Soman, B.D. Kuppermann, M.C. Kenney, Aging 11 (2019) 1177–1188.
[54] H.H.-L. Chan, H.-I. Lam, K.-Y. Choi, S.Z.-C. Li, Y. Lakshmanan, W.-Y. Yu, R.C.-C. Chang, J.S.-M. Lai, K.-F. So, J. Ethnopharmacol. 236 (2019) 336–344.
[55] H.-Y. Li, M. Huang, Q.-Y. Luo, X. Hong, S. Ramakrishna, K.-F. So, Cell Transplant. 28 (2019) 607–618.
[56] H. Li, Y. Liang, K. Chiu, Q. Yuan, B. Lin, R.C.-C. Chang, K.-F. So, PLoS One 8 (2013) e68881.
[57] D. Yang, K.-F. So, A.C. Lo, Clin. Experiment. Ophthalmol. 45 (2017) 717–729.
[58] Q. Yao, Y. Yang, X. Lu, Q. Zhang, M. Luo, P.A. Li, Y. Pan, Evid. Based. Complement. Alternat. Med. 2018 (2018) 7943212.
[59] F. Liu, J. Zhang, Z. Xiang, D. Xu, K.-F. So, N. Vardi, Y. Xu, Invest. Ophthalmol. Vis. Sci. 59 (2018) 597–611.
[60] L. Liu, X.-Y. Sha, Y.-N. Wu, M.-T. Chen, J.-X. Zhong, Neural Regeneration Res. 15 (2020) 1526–1531.
[61] S.-Y. Li, D. Yang, C.-M. Yeung, W.-Y. Yu, R.C.-C. Chang, K.-F. So, D. Wong, A.C.Y. Lo, PLoS One 6 (2011) e16380.
[62] X.-S. Mi, Q. Feng, A.C.Y. Lo, R.C.-C. Chang, S.K. Chung, K.-F. So, Neural Regeneration Res. 15 (2020) 2344–2352.
[63] Y. Lakshmanan, F.S.-Y. Wong, W.-Y. Yu, S.Z.-C. Li, K.-Y. Choi, K.-F. So, H.H.-L. Chan, Invest. Ophthalmol. Vis. Sci. 60 (2019) 2023–2033.
[64] Y. Lakshmanan, F.S.Y. Wong, B. Zuo, K.-F. So, B.V. Bui, H.H.-L. Chan, Invest. Ophthalmol. Vis. Sci. 60 (2019) 4606–4618.
[65] M. Yang, K.-F. So, A.C.Y. Lo, W.C. Lam, Int. J. Mol. Sci. 21 (2020).
[66] C.-K. Hu, Y.-J. Lee, C.M. Colitz, C.-J. Chang, C.-T. Lin, Vet. Ophthalmol. 15 Suppl 2 (2012) 65–71.
[67] P.H.W. Chu, H.-Y. Li, M.-P. Chin, K.-F. So, H.H.L. Chan, PLoS One 8 (2013) e81339.
[68] C. Sampath, Y. Zhu, S. Sang, M. Ahmedna, Phytomedicine 23 (2016) 200–213.
[69] A. Lashay, G. Sadough, E. Ashrafi, M. Lashay, M. Movassat, S. Akhondzadeh, Med Hypothesis Discov Innov Ophthalmol 5 (2016) 32–38.
[70] M. Piccardi, D. Marangoni, A.M. Minnella, M.C. Savastano, P. Valentini, L. Ambrosio, E. Capoluongo, R. Maccarone, S. Bisti, B. Falsini, Evid. Based. Complement. Alternat. Med. 2012 (2012) 429124.
[71] B. Falsini, M. Piccardi, A. Minnella, C. Savastano, E. Capoluongo, A. Fadda, E. Balestrazzi, R. Maccarone, S. Bisti, Invest. Ophthalmol. Vis. Sci. 51 (2010) 6118–6124.
[72] L.-Y. Dong, J. Jin, G. Lu, X.-L. Kang, Mar. Drugs 11 (2013) 960–974.
[73] A. Cort, N. Ozturk, D. Akpinar, M. Unal, G. Yucel, A. Ciftcioglu, P. Yargicoglu, M. Aslan, Regul. Toxicol. Pharmacol. 58 (2010) 121–130.
[74] P.-T. Yeh, H.-W. Huang, C.-M. Yang, W.-S. Yang, C.-H. Yang, PLoS One 11 (2016) e0146438.
[75] Y. Tao, M. He, Q. Yang, Z. Ma, Y. Qu, W. Chen, G. Peng, D. Teng, Drug Des. Devel. Ther. 13 (2019) 2689–2702.
[76] Y. Fan, J. Lai, Y. Yuan, L. Wang, Q. Wang, F. Yuan, Curr. Eye Res. 45 (2020) 52–63.
[77] A.J.A. Jafri, R. Agarwal, I. Iezhitsa, P. Agarwal, N.M. Ismail, Amino Acids 51 (2019) 641–646.
[78] N. Froger, F. Jammoul, D. Gaucher, L. Cadetti, H. Lorach, J. Degardin, D. Pain, E. Dubus, V. Forster, I. Ivkovic, M. Simonutti, J.-A. Sahel, S. Picaud, Adv. Exp. Med. Biol. 775 (2013) 69–83.
[79] N. Froger, L. Cadetti, H. Lorach, J. Martins, A.-P. Bemelmans, E. Dubus, J. Degardin, D. Pain, V. Forster, L. Chicaud, I. Ivkovic, M. Simonutti, S. Fouquet, F. Jammoul, T. Léveillard, R. Benosman, J.-A. Sahel, S. Picaud, PLoS One 7 (2012) e42017.
[80] K. Zeng, H. Xu, M. Mi, K. Chen, J. Zhu, L. Yi, T. Zhang, Q. Zhang, X. Yu, Neurochem. Res. 35 (2010) 1566–1574.
[81] X. Yu, Z. Xu, M. Mi, H. Xu, J. Zhu, N. Wei, K. Chen, Q. Zhang, K. Zeng, J. Wang, F. Chen, Y. Tang, Neurochem. Res. 33 (2008) 500–507.
[82] X. Yu, K. Chen, N. Wei, Q. Zhang, J. Liu, M. Mi, Br. J. Nutr. 98 (2007) 711–719.
[83] W. Hadj-Saïd, V. Fradot, I. Ivkovic, J.-A. Sahel, S. Picaud, N. Froger, Adv. Exp. Med. Biol. 975 Pt 2 (2017) 687–701.
[84] Z. Jiang, S. Bulley, J. Guzzone, H. Ripps, W. Shen, Adv. Exp. Med. Biol. 775 (2013) 53–68.
[85] J. Kim, C.-S. Kim, Y.M. Lee, E. Sohn, K. Jo, J.S. Kim, Int. J. Food Sci. Nutr. 66 (2015) 236–242.
[86] J. Wang, Y. Yao, X. Liu, K. Wang, Q. Zhou, Y. Tang, Am. J. Transl. Res. 11 (2019) 6304–6315.
[87] X.-S. Mi, K. Chiu, G. Van, J.W.C. Leung, A.C.Y. Lo, S.K. Chung, R.C.-C. Chang, K.-F. So, Neural Regeneration Res. 7 (2012) 645–651.
[88] H. Wang, B.W.-M. Lau, N.-L. Wang, S.-Y. Wang, Q.-J. Lu, R.C.-C. Chang, K.-F. So, Neural Regeneration Res. 10 (2015) 1976–1981.
[89] D. Stambolian, M. Behrens, Am. J. Ophthalmol. 83 (1977) 465–468.
[90] A.J. Larner, Int. J. Clin. Pract. 58 (2004) 977–978.
[91] E.M. Chester, D.P. Agamanolis, J.W. Harris, M. Victor, J.D. Hines, J.A. Kark, Acta Neurol. Scand. 61 (1980) 9–26.
[92] M. Moschos, The Lancet 352 (1998) 146–147.
[93] Y. Yamazaki, F. Hayamizu, C. Tanaka, Curr. Ther. Res. Clin. Exp. 61 (2000) 443–451.
[94] X. Kong, X. Sun, J. Zhang, Yan Ke Xue Bao 20 (2004) 171–177.
[95] S.H. Chavala, G.S. Kosmorsky, M.K. Lee, M.S. Lee, Eur. J. Intern. Med. 16 (2005) 447–448.
[96] P. Enoksson, A. Norden, Acta Medica Scandinavica 167 (2009) 199–208.
[97] C. Chu, P. Scanlon, Case Reports 2011 (2011) bcr0220113823–bcr0220113823.
[98] O.P. Anand, Delhi Journal of Ophthalmology 29 (2019).
[99] H.-Y. Li, Y.-W. Ruan, P.W.-F. Kau, K. Chiu, R.C.-C. Chang, H.H.L. Chan, K.-F. So, Cell Transplant. 24 (2015) 403–417.
[100] N.N. Nor Arfuzir, R. Agarwal, I. Iezhitsa, P. Agarwal, S. Sidek, N.M. Ismail, Neural Regeneration Res. 13 (2018) 2014–2021.
[101] N. Kavitha Nair, K. Patel, T. Gandhi, Iran J Pharm Res 9 (2010) 147–152.
[102] J. Banot, G. Lata, O.P. Jangir, M. Sharma, V.S. Rathore, S.K. Saini, A. Nagal, Indian J. Exp. Biol. 47 (2009) 157–162.
[103] P. Suryanarayana, P.A. Kumar, M. Saraswat, J.M. Petrash, G.B. Reddy, Mol. Vis. 10 (2004) 148–154.
[104] Q. Yao, Y. Zhou, Y. Yang, L. Cai, L. Xu, X. Han, Y. Guo, P.A. Li, J. Ethnopharmacol. 261 (2020) 113165.
[105] B. Qi, Q. Ji, Y. Wen, L. Liu, X. Guo, G. Hou, G. Wang, J. Zhong, PLoS One 9 (2014) e110275.
[106] M. Saraswat, P. Suryanarayana, P.Y. Reddy, M.A. Patil, N. Balakrishna, G.B. Reddy, Mol. Vis. 16 (2010) 1525–1537.
[107] A. Kato, Y. Higuchi, H. Goto, H. Kizu, T. Okamoto, N. Asano, J. Hollinshead, R.J. Nash, I. Adachi, J. Agric. Food Chem. 54 (2006) 6640–6644.
[108] J. Song, Y. Li, J. Ge, Y. Duan, S.C.-W. Sze, Y. Tong, P.-C. Shaw, T.-B. Ng, K.C. Tsui, Y. Zhuo, K.Y. Zhang, Phytother. Res. 24 (2010) 520–524.
[109] F. Harada, T. Morikawa, A. Lennikov, A. Mukwaya, M. Schaupper, O. Uehara, R. Takai, K. Yoshida, J. Sato, Y. Horie, H. Sakaguchi, C.-Z. Wu, Y. Abiko, N. Lagali, N. Kitaichi, Oxid. Med. Cell. Longev. 2017 (2017) 1956104.
[110] H. Li, J. Li, C. Hou, J. Li, H. Peng, Q. Wang, Exp. Eye Res. 197 (2020) 108113.
[111] T. Shimokawa, M. Yoshida, T. Fukuta, T. Tanaka, T. Inagi, K. Kogure, J. Clin. Biochem. Nutr. 64 (2019) 27–35.
[112] T. Shimokawa, T. Fukuta, T. Inagi, K. Kogure, J. Clin. Biochem. Nutr. 66 (2020) 224–232.
[113] S. Ozen, M.A. Ozer, M.O. Akdemir, Graefes Arch. Clin. Exp. Ophthalmol. 255 (2017) 1173–1177.
[114] M.R. Romano, F. Biagioni, A. Carrizzo, M. Lorusso, A. Spadaro, T. Micelli Ferrari, C. Vecchione, M. Zurria, G. Marrazzo, G. Mascio, B. Sacchetti, M. Madonna, F. Fornai, F. Nicoletti, M.D. Lograno, Exp. Eye Res. 120 (2014) 109–117.
[115] A.A. Heinämäki, A.S. Muhonen, R.S. Piha, Neurochem. Res. 11 (1986) 535–542.
[116] C. Bucolo, A. Fidilio, C.B.M. Platania, F. Geraci, F. Lazzara, F. Drago, J. Ocul. Pharmacol. Ther. 34 (2018) 188–194.
[117] R. Shioda, P.S. Reinach, T. Hisatsune, Y. Miyamoto, Invest. Ophthalmol. Vis. Sci. 43 (2002) 2916–2922.
[118] A.A. Heinämäki, Acta Chem. Scand. B 42 (1988) 39–42.
[119] S.I. Baskin, E.M. Cohn, Kocsis, Exp. Eye Res. 24 (1977) 315–319.
[120] M. Fris, M.-B. Tessem, J. Cejková, A. Midelfart, Arbeitsphysiologie 244 (2006) 1680–1687.
[121] M. Kosehira, N. Machida, N. Kitaichi, Nutrients 12 (2020).
[122] T. Iwasaki, S. Kurimoto, J. UOEH 9 (1987) 127–132.
[123] Y. Nagaki, H. Tsukahara, T. Yoshimoto, K. Masuda, Folia Ophthalomogica Japonica. 5 (2010) 461–468.
[124] Y. Nagaki, S. Hayasaka, T. Yamada, Y. Hayasaka, M. Sanada, T. Uonomi, (2002).
[125] Y. Uchino, M. Uchino, M. Dogru, K. Fukagawa, K. Tsubota, J. Nutr. Health Aging 16 (2012) 478–481.
[126] S. Kurimoto, T. Iwasaki, T. Nomura, K. Noro, S. Yamamoto, J. UOEH 5 (1983) 101–110.
[127] N.L. Himebaugh, C.G. Begley, A. Bradley, J.A. Wilkinson, Optom. Vis. Sci. 86 (2009) E106–14.
[128] C.K. Choy, P. Cho, W.Y. Chung, I.F. Benzie, Invest. Ophthalmol. Vis. Sci. 42 (2001) 3130–3134.
[129] S. Patel, R. Henderson, L. Bradley, B. Galloway, L. Hunter, Optom. Vis. Sci. 68 (1991) 888–892.
[130] N. Freudenthaler, H. Neuf, G. Kadner, T. Schlote, Graefes Arch. Clin. Exp. Ophthalmol. 241 (2003) 914–920.
[131] R. Singh, A. Joseph, T. Umapathy, N.L. Tint, H.S. Dua, Br. J. Ophthalmol. 89 (2005) 1655–1659.
[132] J.K. Portello, M. Rosenfield, C.A. Chu, Optom. Vis. Sci. 90 (2013) 482–487.
[133] M. Rosenfield, S. Jahan, K. Nunez, K. Chan, Comput. Human Behav. 51 (2015) 403–406.
[134] D.J. Kim, C.Y. Lim, N. Gu, C.Y. Park, Korean J. Ophthalmol. 31 (2017) 388–393.
[135] J.-W. Lee, H.G. Cho, B.-Y. Moon, S.-Y. Kim, D.-S. Yu, PeerJ 7 (2019) e7050.
[136] A. Riva, S. Togni, F. Franceschi, S. Kawada, Y. Inaba, R. Eggenhoffner, L. Giacomelli, Eur. Rev. Med. Pharmacol. Sci. 21 (2017) 2518–2525.
[137] A. Nakata, Others, 薬理と治療 44 (2016) 1773–1783.
[138] X. Ouyang, J. Yang, Z. Hong, Y. Wu, Y. Xie, G. Wang, Biomed. Pharmacother. 130 (2020) 110577.
[139] M. Schieber, N.S. Chandel, Curr. Biol. 24 (2014) R453–62.
[140] J. Loughman, P.A. Davison, J.M. Nolan, M.C. Akkali, S. Beatty, J. Optom. 3 (2010) 74–90.
[141] B.R. Hammond, L.M. Fletcher, F. Roos, J. Wittwer, W. Schalch, Invest. Ophthalmol. Vis. Sci. 55 (2014) 8583–8589.
[142] J.M. Stringham, P.V. Garcia, P.A. Smith, L.N. McLin, B.K. Foutch, Invest. Ophthalmol. Vis. Sci. 52 (2011) 7406–7415.
[143] J. Loughman, M.C. Akkali, S. Beatty, G. Scanlon, P.A. Davison, V. O’Dwyer, T. Cantwell, P. Major, J. Stack, J.M. Nolan, Vision Res. 50 (2010) 1249–1256.
[144] P. Bhosale, B. Serban, P.S. Bernstein, Arch. Biochem. Biophys. 483 (2009) 175–181.
[145] S.P. Sundelin, S.E. Nilsson, Free Radic. Biol. Med. 31 (2001) 217–225.
[146] V.C. Lima, R.B. Rosen, M. Farah, Int J Retina Vitreous 2 (2016) 19.
[147] P.S. Bernstein, B. Li, P.P. Vachali, A. Gorusupudi, R. Shyam, B.S. Henriksen, J.M. Nolan, Prog. Retin. Eye Res. 50 (2016) 34–66.
[148] A. Junghans, H. Sies, W. Stahl, Arch. Biochem. Biophys. 391 (2001) 160–164.
[149] A. Kijlstra, Y. Tian, E.R. Kelly, T.T.J.M. Berendschot, Prog. Retin. Eye Res. 31 (2012) 303–315.
[150] A.G. Murillo, S. Hu, M.L. Fernandez, Antioxidants (Basel) 8 (2019).
[151] L. Ma, R. Liu, J.H. Du, T. Liu, S.S. Wu, X.H. Liu, Nutrients 8 (2016).
[152] A. Obana, Y. Gohto, R. Nakazawa, T. Moriyama, W. Gellermann, P.S. Bernstein, Sci. Rep. 10 (2020) 10262.
[153] N. Machida, M. Kosehira, N. Kitaichi, Nutrients 12 (2020).
[154] Y. Yao, Q.-H. Qiu, X.-W. Wu, Z.-Y. Cai, S. Xu, X.-Q. Liang, Nutrition 29 (2013) 958–964.
[155] J.M. Nolan, R. Power, J. Stringham, J. Dennison, J. Stack, D. Kelly, R. Moran, K.O. Akuffo, L. Corcoran, S. Beatty, Invest. Ophthalmol. Vis. Sci. 57 (2016) 3429–3439.
[156] J.M. Nolan, J. Loughman, M.C. Akkali, J. Stack, G. Scanlon, P. Davison, S. Beatty, Vision Res. 51 (2011) 459–469.
[157] L.M. Renzi-Hammond, E.R. Bovier, L.M. Fletcher, L.S. Miller, C.M. Mewborn, C.A. Lindbergh, J.H. Baxter, B.R. Hammond, Nutrients 9 (2017).
[158] E.R. Bovier, L.M. Renzi, B.R. Hammond, PLoS One 9 (2014) e108178.
[159] E.R. Bovier, B.R. Hammond, Arch. Biochem. Biophys. 572 (2015) 54–57.
[160] B.R. Hammond Jr, L.S. Miller, M.O. Bello, C.A. Lindbergh, C. Mewborn, L.M. Renzi-Hammond, Front. Aging Neurosci. 9 (2017) 254.
[161] J.M. Stringham, K.J. O’Brien, N.T. Stringham, Eye Vis (Lond) 3 (2016) 30.
[162] J.M. Stringham, N.T. Stringham, K.J. O’Brien, Foods 6 (2017).
[163] L. Ma, X.-M. Lin, Z.-Y. Zou, X.-R. Xu, Y. Li, R. Xu, Br. J. Nutr. 102 (2009) 186–190.
[164] J. Kvansakul, M. Rodriguez-Carmona, D.F. Edgar, F.M. Barker, W. Köpcke, W. Schalch, J.L. Barbur, Ophthalmic Physiol. Opt. 26 (2006) 362–371.
[165] A. Yagi, K. Fujimoto, K. Michihiro, B. Goh, D. Tsi, H. Nagai, Appl. Ergon. 40 (2009) 1047–1054.
[166] E. Ooe, Y. Kuse, T. Yako, T. Sogon, S. Nakamura, H. Hara, M. Shimazawa, Mol. Vis. 24 (2018) 621–632.
[167] T. Otsuka, M. Shimazawa, T. Nakanishi, Y. Ohno, Y. Inoue, K. Tsuruma, T. Ishibashi, H. Hara, J. Pharmacol. Sci. 123 (2013) 209–218.
[168] R. Maccarone, S. Di Marco, S. Bisti, Invest. Ophthalmol. Vis. Sci. 49 (2008) 1254–1261.
[169] F.D. Marco, S. Romeo, C. Nandasena, S. Purushothuman, C. Adams, S. Bisti, J. Stone, Am. J. Neurodegener. Dis. 2 (2013) 208–220.
[170] A. Laabich, G.P. Vissvesvaran, K.L. Lieu, K. Murata, T.E. McGinn, C.C. Manmoto, J.R. Sinclair, I. Karliga, D.W. Leung, A. Fawzi, R. Kubota, Invest. Ophthalmol. Vis. Sci. 47 (2006) 3156–3163.
[171] M. Yamauchi, K. Tsuruma, S. Imai, T. Nakanishi, N. Umigai, M. Shimazawa, H. Hara, Eur. J. Pharmacol. 650 (2011) 110–119.
[172] L. Tang, S. Bao, Y. Du, Z. Jiang, A.O. Wuliji, X. Ren, C. Zhang, H. Chu, L. Kong, H. Ma, Biomed. Pharmacother. 103 (2018) 829–837.
[173] J.-S. Chang, Y.-J. Lee, D.A. Wilkie, C.-T. Lin, J. Vet. Med. Sci. 80 (2018) 1108–1115.
[174] H. Pasantes-Morales, C. Cruz, Brain Res. 330 (1985) 154–157.
[175] W. Dayang, P. Dongbo, Cutan. Ocul. Toxicol. 37 (2018) 240–244.
[176] N.D. Wangsa-Wirawan, R.A. Linsenmeier, Arch. Ophthalmol. 121 (2003) 547–557.
[177] M.T.T. Wong-Riley, Eye Brain 2 (2010) 99–116.
[178] J.-X. Tao, W.-C. Zhou, X.-G. Zhu, Oxid. Med. Cell. Longev. 2019 (2019) 6435364.
[179] S. del Olmo-Aguado, A.G. Manso, N.N. Osborne, Photochem. Photobiol. 88 (2012) 1346–1355.
[180] N.N. Osborne, C. Núñez-Álvarez, S. Del Olmo-Aguado, Exp. Eye Res. 128 (2014) 8–14.
[181] T. Nakanishi-Ueda, H.J. Majima, K. Watanabe, T. Ueda, H.P. Indo, S. Suenaga, T. Hisamitsu, T. Ozawa, H. Yasuhara, R. Koide, Free Radic. Res. 47 (2013) 774–780.
[182] E.K. Ozkaya, G. Anderson, B. Dhillon, P.-O. Bagnaninchi, Exp. Eye Res. 189 (2019) 107817.
[183] V.D. Reddy, P. Padmavathi, G. Kavitha, S. Gopi, N. Varadacharyulu, J. Med. Food 14 (2011) 62–68.
[184] H. Yu, L. Wark, H. Ji, L. Willard, Y. Jaing, J. Han, H. He, E. Ortiz, Y. Zhang, D.M. Medeiros, D. Lin, Mol. Nutr. Food Res. 57 (2013) 1158–1169.
[185] S.V. Rao, Muralidhara, S.C. Yenisetti, P.S. Rajini, Neurotoxicology 52 (2016) 230–242.
[186] B. Lv, T. Chen, Z. Xu, F. Huo, Y. Wei, X. Yang, Int. J. Mol. Med. 37 (2016) 225–232.
[187] D.-H. Lee, C.-S. Kim, Y.J. Lee, Food Chem. Toxicol. 49 (2011) 271–280.
[188] X. Wen, A. Huang, J. Hu, Z. Zhong, Y. Liu, Z. Li, X. Pan, Z. Liu, Neuroscience 303 (2015) 558–568.
[189] X. Liu, T. Shibata, S. Hisaka, T. Osawa, Brain Res. 1254 (2009) 18–27.
[190] S.H. Kim, H. Kim, Nutrients 10 (2018).
[191] A.M. Wolf, S. Asoh, H. Hiranuma, I. Ohsawa, K. Iio, A. Satou, M. Ishikura, S. Ohta, J. Nutr. Biochem. 21 (2010) 381–389.
[192] J.S. Park, B.D. Mathison, M.G. Hayek, J. Zhang, G.A. Reinhart, B.P. Chew, J. Anim. Sci. 91 (2013) 268–275.
[193] Q. Wang, W. Fan, Y. Cai, Q. Wu, L. Mo, Z. Huang, H. Huang, Amino Acids 48 (2016) 2169–2177.
[194] C.J. Jong, J. Azuma, S. Schaffer, Amino Acids 42 (2012) 2223–2232.
[195] S.W. Schaffer, J. Azuma, M. Mozaffari, Can. J. Physiol. Pharmacol. 87 (2009) 91–99.
[196] M.A.S. Di Leo, S.A. Santini, S. Cercone, D. Lepore, N. Gentiloni Silveri, S. Caputo, A.V. Greco, B. Giardina, F. Franconi, G. Ghirlanda, Amino Acids 23 (2002) 401–406.
[197] L. Chen, Y. Qi, X. Yang, Ophthalmic Res. 54 (2015) 157–168.
[198] S. Kausar, F. Wang, H. Cui, Cells 7 (2018).
[199] J. Widomska, W.K. Subczynski, J. Clin. Exp. Ophthalmol. 5 (2014) 326.
[200] W. Grudzinski, L. Nierzwicki, R. Welc, E. Reszczynska, R. Luchowski, J. Czub, W.I. Gruszecki, Sci. Rep. 7 (2017) 9619.
[201] C.M. Mewborn, D.P. Terry, L.M. Renzi-Hammond, B.R. Hammond, L.S. Miller, Arch. Clin. Neuropsychol. 33 (2018) 861–874.
[202] H. Wu, H. Niu, A. Shao, C. Wu, B.J. Dixon, J. Zhang, S. Yang, Y. Wang, Mar. Drugs 13 (2015) 5750–5766.
[203] P. Kidd, Altern. Med. Rev. 16 (2011) 355–364.
[204] J.M. Stringham, E.J. Johnson, B.R. Hammond, Curr Dev Nutr 3 (2019) nzz066.
[205] E.J. Johnson, K. McDonald, S.M. Caldarella, H.-Y. Chung, A.M. Troen, D.M. Snodderly, Nutr. Neurosci. 11 (2008) 75–83.
[206] M. Matysek, S. Mozel, R. Szalak, A. Zacharko-Siembida, K. Obszańska, M.B. Arciszewski, Pol. J. Vet. Sci. 20 (2017) 313–319.
[207] S. Vepsäläinen, H. Koivisto, E. Pekkarinen, P. Mäkinen, G. Dobson, G.J. McDougall, D. Stewart, A. Haapasalo, R.O. Karjalainen, H. Tanila, M. Hiltunen, J. Nutr. Biochem. 24 (2013) 360–370.
[208] J. Li, R. Zhao, Y. Jiang, Y. Xu, H. Zhao, X. Lyu, T. Wu, Food Funct. 11 (2020) 1572–1584.
[209] A. Virel, A. Rehnmark, G. Orädd, S. Olmedo-Díaz, E. Faergemann, I. Strömberg, Eur. J. Neurosci. 42 (2015) 2761–2771.
[210] D. Yang, S.-Y. Li, C.-M. Yeung, R.C.-C. Chang, K.-F. So, D. Wong, A.C.Y. Lo, PLoS One 7 (2012) e33596.
[211] J. Gao, C. Chen, Y. Liu, Y. Li, Z. Long, H. Wang, Y. Zhang, J. Sui, Y. Wu, L. Liu, C. Yang, Life Sci. 121 (2015) 124–134.
[212] W.-J. Liu, H.-F. Jiang, F.U. Rehman, J.-W. Zhang, Y. Chang, L. Jing, J.-Z. Zhang, Int. J. Biol. Sci. 13 (2017) 901–910.
[213] W. Chen, X. Cheng, J. Chen, X. Yi, D. Nie, X. Sun, J. Qin, M. Tian, G. Jin, X. Zhang, PLoS One 9 (2014) e88076.
[214] P. Zhao, R. Zhou, X.-Y. Zhu, G. Liu, Y.-P. Zhao, P.-S. Ma, W. Wu, Y. Niu, T. Sun, Y.-X. Li, J.-Q. Yu, Z.-M. Qian, Neurochem. Res. 42 (2017) 2798–2813.
[215] C.-S. Lam, G.L. Tipoe, K.-F. So, M.-L. Fung, PLoS One 10 (2015) e0117990.
[216] Y. Zhou, Y. Duan, S. Huang, X. Zhou, L. Zhou, T. Hu, Y. Yang, J. Lu, K. Ding, D. Guo, X. Cao, G. Pei, Int. J. Biol. Macromol. 144 (2020) 1004–1012.
[217] S.-Y. Chung, M. Kang, S.-B. Hong, H. Bae, S.-H. Cho, J. Res. Med. Sci. 24 (2019) 102.
[218] A.K. Ruíz-Salinas, R.A. Vázquez-Roque, A. Díaz, G. Pulido, S. Treviño, B. Floran, G. Flores, J. Nutr. Biochem. 83 (2020) 108416.
[219] E. Zhang, S.Y. Yau, B.W.M. Lau, H. Ma, T.M.C. Lee, R.C.-C. Chang, K.F. So, Cell Transplant. 21 (2012) 2635–2649.
[220] I. Husain, S. Zameer, T. Madaan, A. Minhaj, W. Ahmad, A. Iqubaal, A. Ali, A.K. Najmi, Metab. Brain Dis. 34 (2019) 957–965.
[221] M. Golechha, J. Bhatia, D.S. Arya, Indian J. Exp. Biol. 48 (2010) 474–478.
[222] M. Golechha, J. Bhatia, S. Ojha, D.S. Arya, Pharm. Biol. 49 (2011) 1128–1136.
[223] M. Golechha, J. Bhatia, D.S. Arya, J. Environ. Biol. 33 (2012) 95–100.
[224] A. Justin Thenmozhi, M. Dhivyabharathi, T.R. William Raja, T. Manivasagam, M.M. Essa, Nutr. Neurosci. 19 (2016) 269–278.
[225] M.S. Uddin, A.A. Mamun, M.S. Hossain, F. Akter, M.A. Iqbal, M. Asaduzzaman, Ann Neurosci 23 (2016) 218–229.
[226] A. Bhattacharya, S. Ghosal, S.K. Bhattacharya, Indian J. Exp. Biol. 38 (2000) 877–880.
[227] G. Caletti, F.B. Almeida, G. Agnes, M.S. Nin, H.M.T. Barros, R. Gomez, Behav. Brain Res. 283 (2015) 11–15.
[228] N. del Olmo, L.M. Suárez, L.M. Orensanz, F. Suárez, J. Bustamante, J.M. Duarte, R. Martín del Río, J.M. Solís, Eur. J. Neurosci. 19 (2004) 1875–1886.
[229] K. Kuriyama, T. Hashimoto, in: S. Schaffer, J.B. Lombardini, R.J. Huxtable (Eds.), Taurine 3: Cellular and Regulatory Mechanisms, Springer US, Boston, MA, 1998, pp. 329–337.
[230] M.H. Bureau, R.W. Olsen, Eur. J. Pharmacol. 207 (1991) 9–16.
[231] P. Kontro, S.S. Oja, Neuropharmacology 29 (1990) 243–247.
[232] F. Franconi, G. Diana, A. Fortuna, G. Galietta, G. Trombetta, G. Valentini, G. Seghieri, A. Loizzo, Brain Res. Bull. 63 (2004) 491–497.
[233] S. Baziar, A. Aqamolaei, E. Khadem, S.H. Mortazavi, S. Naderi, E. Sahebolzamani, A. Mortezaei, S. Jalilevand, M.-R. Mohammadi, M. Shahmirzadi, S. Akhondzadeh, J. Child Adolesc. Psychopharmacol. 29 (2019) 205–212.
[234] H. Ettehadi, S.N. Mojabi, M. Ranjbaran, J. Shams, H. Sahraei, M. Hedayati, F. Asefi, JBBS 03 (2013) 315–319.
[235] B. Naghizadeh, M.T. Mansouri, B. Ghorbanzadeh, Y. Farbood, A. Sarkaki, Phytomedicine 20 (2013) 537–542.
[236] S. Purushothuman, C. Nandasena, C.L. Peoples, N. El Massri, D.M. Johnstone, J. Mitrofanis, J. Stone, J. Parkinsons. Dis. 3 (2013) 77–83.
[237] Y.S. Batarseh, S.S. Bharate, V. Kumar, A. Kumar, R.A. Vishwakarma, S.B. Bharate, A. Kaddoumi, ACS Chem. Neurosci. 8 (2017) 1756–1766.
[238] L. Tamegart, A. Abbaoui, R. Makbal, M. Zroudi, B. Bouizgarne, M.M. Bouyatas, H. Gamrani, Acta Histochem. 121 (2019) 171–181.
[239] P. Haeri, A. Mohammadipour, Z. Heidari, A. Ebrahimzadeh-Bideskan, Anat. Sci. Int. 94 (2019) 119–127.
[240] S. Soeda, K. Aritake, Y. Urade, H. Sato, Y. Shoyama, Adv Neurobiol 12 (2016) 275–292.
[241] M. Masaki, K. Aritake, H. Tanaka, Y. Shoyama, Z.-L. Huang, Y. Urade, Mol. Nutr. Food Res. 56 (2012) 304–308.
[242] Z. Liu, X.-H. Xu, T.-Y. Liu, Z.-Y. Hong, Y. Urade, Z.-L. Huang, W.-M. Qu, CNS Neurosci. Ther. 18 (2012) 623–630.
[243] M. Farokhnia, M. Shafiee Sabet, N. Iranpour, A. Gougol, H. Yekehtaz, R. Alimardani, F. Farsad, M. Kamalipour, S. Akhondzadeh, Hum. Psychopharmacol. 29 (2014) 351–359.
[244] S. Akhondzadeh, M.S. Sabet, M.H. Harirchian, M. Togha, H. Cheraghmakani, S. Razeghi, S.S. Hejazi, M.H. Yousefi, R. Alimardani, A. Jamshidi, F. Zare, A. Moradi, J. Clin. Pharm. Ther. 35 (2010) 581–588.
[245] S. Akhondzadeh, M. Shafiee Sabet, M.H. Harirchian, M. Togha, H. Cheraghmakani, S. Razeghi, S.S. Hejazi, M.H. Yousefi, R. Alimardani, A. Jamshidi, S.-A. Rezazadeh, A. Yousefi, F. Zare, A. Moradi, A. Vossoughi, Psychopharmacology 207 (2010) 637–643.
[246] G. Park, H.G. Kim, M.S. Ju, S.K. Ha, Y. Park, S.Y. Kim, M.S. Oh, Acta Pharmacol. Sin. 34 (2013) 1131–1139.
[247] E. Huh, S. Lim, H.G. Kim, S.K. Ha, H.-Y. Park, Y. Huh, M.S. Oh, Food Funct. 9 (2018) 171–178.
[248] J. Yao, C. Ge, D. Duan, B. Zhang, X. Cui, S. Peng, Y. Liu, J. Fang, J. Agric. Food Chem. 62 (2014) 5507–5518.
[249] G.-F. Zeng, Z.-Y. Zhang, L. Lu, D.-Q. Xiao, S.-H. Zong, J.-M. He, Rejuvenation Res. 16 (2013) 124–133.
[250] N. Saenghong, J. Wattanathorn, S. Muchimapura, T. Tongun, N. Piyavhatkul, C. Banchonglikitkul, T. Kajsongkram, Evid. Based. Complement. Alternat. Med. 2012 (2012) 383062.
[251] S. Lim, M. Moon, H. Oh, H.G. Kim, S.Y. Kim, M.S. Oh, J. Nutr. Biochem. 25 (2014) 1058–1065.
[252] C.S. Pavlov, I.V. Damulin, Y.O. Shulpekova, E.A. Andreev, Ter. Arkh. 91 (2019) 122–129.
[253] I.A.N. Omar, Clin. Ophthalmol. 12 (2018) 2575–2579.
[254] K. Kamiya, H. Kobashi, K. Fujiwara, W. Ando, K. Shimizu, J. Ocul. Pharmacol. Ther. 29 (2013) 356–359.
[255] S.H. Shim, J.M. Kim, C.Y. Choi, C.Y. Kim, K.H. Park, J. Med. Food 15 (2012) 818–823.
[256] Y. Ozawa, M. Kawashima, S. Inoue, E. Inagaki, A. Suzuki, E. Ooe, S. Kobayashi, K. Tsubota, J. Nutr. Health Aging 19 (2015) 548–554.
[257] R.D. Steigerwalt Jr, B. Gianni, M. Paolo, E. Bombardelli, C. Burki, F. Schönlau, Mol. Vis. 14 (2008) 1288.
[258] S. Piermarocchi, S. Saviano, V. Parisi, M. Tedeschi, G. Panozzo, G. Scarpa, G. Boschi, G. Lo Giudice, Carmis Study Group, Eur. J. Ophthalmol. 22 (2012) 216–225.
[259] Y. Seya, J. Takahashi, K. Imanaka, Japanese Journal of Physiological Anthropology 14 (2009) 59–66.
[260] M. Saito, K. Yoshida, W. Saito, A. Fujiya, K. Ohgami, N. Kitaichi, H. Tsukahara, S. Ishida, S. Ohno, Graefes Arch. Clin. Exp. Ophthalmol. 250 (2012) 239–245.
[261] Y. Nagaki, M. Mihara, J. Takahashi, A. Kitamura, Y. Horita, Y. Sugiura, H. Tsukahara, Altern. Med. Rev. 21 (2005) 537–542.
[262] G.K. Broadhead, J.R. Grigg, P. McCluskey, T. Hong, T.E. Schlub, A.A. Chang, Graefes Arch. Clin. Exp. Ophthalmol. 257 (2019) 31–40.
[263] K.-J. Chien, C.-T. Horng, Y.-S. Huang, Y.-H. Hsieh, C.-J. Wang, J.-S. Yang, C.-C. Lu, F.-A. Chen, Mol. Med. Rep. 17 (2018) 809–818.
[264] S. Xu, S. Liu, G. Yan, Med. Sci. Monit. 25 (2019) 9794–9800.
[265] S.S. Yadav, M.K. Singh, P.K. Singh, V. Kumar, Biomed. Pharmacother. 93 (2017) 1292–1302.
[266] B.C. Variya, A.K. Bakrania, S.S. Patel, Pharmacol. Res. 111 (2016) 180–200.
[267] S. Dasaroju, K.M. Gottumukkala, Int J Pharm Sci Rev Res 24 (2014) 150–159.
[268] U. Vishwanatha, K.P. Guruprasad, P.M. Gopinath, R.V. Acharya, B.V. Prasanna, J. Nayak, R. Ganesh, J. Rao, R. Shree, S. Anchan, K.S. Raghu, M.B. Joshi, P. Paladhi, P.M. Varier, K. Muraleedharan, T.S. Muraleedharan, K. Satyamoorthy, J. Ethnopharmacol. 191 (2016) 387–397.
[269] K.P. Guruprasad, S. Dash, M.B. Shivakumar, P.R. Shetty, K.S. Raghu, B.R. Shamprasad, V. Udupi, R.V. Acharya, P.B. Vidya, J. Nayak, A.E. Mana, R. Moni, M.T. Sankaran, K. Satyamoorthy, J. Ayurveda Integr. Med. 8 (2017) 105–112.
[270] M. Zhang, L.F. Bi, Y.D. Ai, L.P. Yang, H.B. Wang, Z.Y. Liu, M. Sekine, S. Kagamimori, Amino Acids 26 (2004) 59–63.
Elizabeth Kennedy